SPA
KALV

Sherbrooke Park Advisers’s KalVista Pharmaceuticals KALV Stock Holding History

Sherbrooke Park Advisers’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$184K Sell
11,424
-4,254
-27% -$56.3K 0.48% 96
2025
Q3 		$191K Buy
+15,678
New +$217K 0.09% 391

Other funds holding KALV

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Sherbrooke Park Advisers's KALV Position: Q4 2025 in Review

Sherbrooke Park Advisers reduced its KalVista Pharmaceuticals (KALV) stake by 27% in Q4 2025, selling an estimated $56.3K and leaving 11,424 shares worth $184K. The position accounts for 0.48% of the portfolio, ranked #96.

Sherbrooke Park Advisers first reported a position in KALV in Q3 2025 and has held it in 2 quarters since. The position peaked at $191K in Q3 2025. 161 funds tracked by Wall St. Rank hold KALV as of Q4 2025.

  • Sherbrooke Park Advisers held 11,424 shares of KalVista Pharmaceuticals worth $184K as of Q4 2025.
  • Sherbrooke Park Advisers sold 4,254 KalVista Pharmaceuticals shares in Q4 2025, an estimated $56.3K.
  • KalVista Pharmaceuticals made up 0.48% of Sherbrooke Park Advisers's portfolio in Q4 2025, its #96 holding.
  • Sherbrooke Park Advisers first reported a position in KalVista Pharmaceuticals in Q3 2025 and has held it in 2 quarters since.
  • Sherbrooke Park Advisers's KalVista Pharmaceuticals position peaked at $191K in Q3 2025.
  • 161 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q4 2025.

Based on Sherbrooke Park Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.